Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/ABT-510> ?p ?o }
Showing triples 1 to 26 of
26
with 100 triples per page.
- ABT-510 abstract "ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a \"subcutaneously (SC) administered nonapeptide thrombospondin analogue.\"Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study. Only three out of twenty-one patients reached the primary endpoint of progression-free survival at 18 weeks, but these three patients remained progression-free for 21, 34, and 42 weeks. However, biomarker data collected during this study showed a decrease in VEGF-C, circulating endothelial cells, and CD146 and CD34/133 counts, and a maximum tolerated dose has still not been established. Further study could consider a higher dose and/or combination treatment.".
- ABT-510 wikiPageID "12223250".
- ABT-510 wikiPageLength "1892".
- ABT-510 wikiPageOutDegree "7".
- ABT-510 wikiPageRevisionID "659773311".
- ABT-510 wikiPageWikiLink CD146.
- ABT-510 wikiPageWikiLink Category:Angiogenesis_inhibitors.
- ABT-510 wikiPageWikiLink Clinical_endpoint.
- ABT-510 wikiPageWikiLink Clinical_trial.
- ABT-510 wikiPageWikiLink Melanoma.
- ABT-510 wikiPageWikiLink Vascular_endothelial_growth_factor_C.
- ABT-510 wikiPageWikiLinkText "ABT-510".
- ABT-510 wikiPageUsesTemplate Template:Reflist.
- ABT-510 subject Category:Angiogenesis_inhibitors.
- ABT-510 hypernym Drug.
- ABT-510 type Drug.
- ABT-510 type Drug.
- ABT-510 type Inhibitor.
- ABT-510 type Redirect.
- ABT-510 comment "ABT-510 is a molecular therapeutic drug that was the subject of research as a potential treatment for cancer. According to the Journal of Clinical Oncology, ABT-510 is a \"subcutaneously (SC) administered nonapeptide thrombospondin analogue.\"Following inconclusive phase I clinical trials, a 2007 phase II study of ABT-510 for treatment of metastatic melanoma failed to reach its primary endpoint resulting in termination of the study.".
- ABT-510 label "ABT-510".
- ABT-510 sameAs Q4650419.
- ABT-510 sameAs m.02vwf_6.
- ABT-510 sameAs Q4650419.
- ABT-510 wasDerivedFrom ABT-510?oldid=659773311.
- ABT-510 isPrimaryTopicOf ABT-510.